Acute lymphoblastic leukemia (ALL) is a type of cancer of the blood and bone marrow that affects white blood cells. These white blood cells are important to your immune system because they play a role in helping your body fight infection and disease. But when you have ALL, the bone marrow makes too many of these white blood cells and they do not work properly.1,2
After being treated for ALL, children may achieve remission. This means that all signs and symptoms of cancer have decreased or disappeared.1
Sometimes cancer cells return. This is called a relapse.1
Or a child may be treated and not reach remission. This is called refractory disease.1
BLINCYTO® is a prescription medicine used to treat a certain type of acute lymphoblastic leukemia (ALL) in adults and children.3
BLINCYTO® is an immunotherapy, not a chemotherapy. An immunotherapy is a type of treatment that engages with parts of your body’s own immune system to fight diseases such as cancer.1,3
In a study, young people ranging in age from 7 months to 17 years with relapsed or refractory B-cell precursor ALL were treated with BLINCYTO®.3
Some people had more than one relapse before the study. Others may have had a relapse following a stem cell transplantation prior to getting
BLINCYTO®, or for some their cancer may have been refractory to other treatments.3
In a study of 70 children with B-cell precursor ALL,
Complete response means there were no signs of cancer after treatment and blood tests for certain kinds of cells fully
recovered to normal or partially recovered to normal within the first 2 treatment cycles.1,3
During treatment with BLINCYTO®, your health care provider will check for symptoms, which can be suggestive of serious side effects that can be severe or life-threatening.
It is also important to notify your health care provider of any side effects you may be having. If certain side effects are observed, your health care provider may change the dose, or delay, or completely stop BLINCYTO® treatment.
Serious side effects that can occur during BLINCYTO® treatment include cytokine release syndrome (CRS), infusion reactions, and neurologic problems.
Tell your health care provider right away if you develop an infection or fever.
Tell your health care provider if you have any side effects that bother you or do not go away.
These are not all the possible side effects of BLINCYTO®.
What is the most important information I should know about BLINCYTO®?
Who should not receive BLINCYTO®?
What should I avoid while receiving BLINCYTO®?
Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:
BLINCYTO® (blinatumomab) is a prescription medication used to treat a certain type of acute lymphoblastic leukemia (ALL) in adults and children. ALL is a cancer of the blood and bone marrow in which a particular kind of white blood cell is replicating out of control.
References: 1. National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed October 9, 2019. 2. Children’s Hospital of Philadelphia. Acute Lymphoblastic Leukemia (ALL). https://www.chop.edu/conditions-diseases/acute-lymphoblastic-leukemia-all. Accessed October 9, 2019. 3. BLINCYTO® (blinatumomab) prescribing information, Amgen. 4. BLINCYTO® (blinatumomab) medication guide, Amgen.